country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-189466

Copy Link Print Information

EGFR-IN-219

EGFR-IN-219 is an EGFR inhibitor. EGFR-IN-219 induces Apoptosis and G0/G1 cell cycle arrest. EGFR-IN-219 exhibits selective anticancer activity against lung adenocarcinoma. EGFR-IN-219 can be used for research on non-small cell lung cancer.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Formule: C₁₇H₁₁BrN₄O₄S
Masse moléculaire:447.26

Stockage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (278 KB)

EGFR-IN-219 Chemical Structure

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Use of MCE Products

One-stop solution for XDC (ADC/PDC/RDC/ApDC/FDC/ISAC/VDC/SMDC)

Activité biologique
- Description
- Cellular Effect
- In Vitro
Chemical Information
Pureté et documentation
Références
Calculators
Help & FAQs
Classifications
Bioz

Activité biologique

Description

Voir tous les produits spécifiques à Isoform EGFR :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC50	6.10 μM	Cytotoxicity against human A549 lung adenocarcinoma cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay. Cytotoxicity against human A549 lung adenocarcinoma cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay.	42612271
L929	IC50	>500 μM	Cytotoxicity against mouse L929 embryonic fibroblast cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay. Cytotoxicity against mouse L929 embryonic fibroblast cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay.	42612271
A549	IC50	2.68 μM	Inhibition of EGFR in human A549 lung adenocarcinoma cells incubated for 24 hrs by colorimetric In-Cell ELISA assay. Inhibition of EGFR in human A549 lung adenocarcinoma cells incubated for 24 hrs by colorimetric In-Cell ELISA assay.	42612271

In Vitro

Anti-cancerApoptosisCell Cycle RegulationOthers

Anti-cancer

EGFR-IN-219 (Compound 2b) (24 h) exhibits potent and selective cytotoxicity against A549 lung adenocarcinoma cells, with an IC₅₀ of 6.10 μM^[1].

Apoptosis

EGFR-IN-219 (6.10 μM; 24 h) induces apoptosis in A549 cells, with an early apoptosis rate of 7.13% and a late apoptosis rate of 1.60%, although its high cytotoxic potency may involve non-apoptotic cell death modes^[1].

Anti-cancer

Cell Cycle Regulation

EGFR-IN-219 (6.10 μM; 24 h) induces cell cycle arrest at the G0/G1 phase in A549 cells, with 65.23% of cells in the G0/G1 phase^[1].

Others

EGFR-IN-219 (24 h) acts as a potent EGFR inhibitor in A549 cells with an IC₅₀ of 2.68 μM, exhibiting 8.3-fold stronger EGFR inhibitory potency and 12.7-fold stronger cytotoxic activity than Erlotinib (HY-50896)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis^[1]

Cell Line:

A549
Concentration:

IC50 concentration
Incubation Time:

24 h
Result:

Induced 7.13% early apoptosis and 1.60% late apoptosis in A549 cells.

Cell Cycle Analysis^[1]

Cell Line:

A549
Concentration:

IC50 concentration
Incubation Time:

24 h
Result:

Induced cell cycle arrest with 65.23% of cells in G0/G1 phase, 20.44% in S phase, and 8.69% in G2/M phase.

Related Protocols :

Chemical Information

Masse moléculaire 447.26
Formule C₁₇H₁₁BrN₄O₄S
SMILES

O=[N+](C1=CC=C(C2=CSC(N/N=C/C3=C(Br)C=C(OCO4)C4=C3)=N2)C=C1)[O-]
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage

Please store the product under the recommended conditions in the Certificate of Analysis.

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (278 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Altıntop MD, et al. Development of thiazole-hydrazone hybrids for targeted therapy of non-small cell lung cancer. Bioorganic chemistry. 2026 Oct 05;181:110369.

Calculators

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Obtenir un devis En stock

Other size

Obtenir un devis